Novo Chairman Faces Testy Investors With Little Progress So Far

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the worldAmericas+1 212 318 2000EMEA+44 20 7330 7500Asia Pacific+65 6212 1000Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the worldAmericas+1 212 318 2000EMEA+44 20 7330 7500Asia Pacific+65 6212 1000Weight-Loss Drugs:Lars Rebien Sorensen Photographer: Simon Dawson/BloombergNovo Nordisk A/S’s Chairman Lars Rebien Sorensen will face investors at the company’s annual meeting for the first time on Thursday after his boardroom coup. He’s in for an earful. Sorensen and new Chief Executive Officer Mike Doustdar have had just months to start remaking Novo as a more aggressive and fast-moving company, but investors point to two recent missteps. The drugmaker failed in an attempt last fall to wrest an obesity startup away from Pfizer Inc. And it surprised the market this year with a gloomy forecast that sent shares plunging.